Progress in the Development and Medical Applications of PET/SPECT Radiotracers and Theranostics
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".
Deadline for manuscript submissions: 31 March 2025 | Viewed by 82
Special Issue Editor
Interests: metabolism and cancer; nuclear medicine; radiochemistry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This proposed Special Issue aims to explore the future directions in the development and medical applications of PET (Positron Emission Tomography) and SPECT (Single-Photon Emission Computed Tomography) radiotracers, focusing on theranostics. As imaging technologies and radiotracer chemistry continue to evolve, this Special Issue will provide an in-depth analysis of emerging trends, technological advancements, and their potential impact on clinical practice.
Objectives:
- Review Current Advances: Summarize recent PET and SPECT radiotracer advancements, including novel compounds and improved imaging techniques. Assess how these advancements have enhanced diagnostic accuracy and therapeutic monitoring.
- Explore Theranostics: Investigate the integration of radiotracers with therapeutic agents in theranostics. Discuss examples of current theranostic approaches, their clinical trials, and their potential for personalized medicine.
- Identify Future Trends: Predict future developments in radiotracer technology, including the role of artificial intelligence and machine learning in improving image analysis and patient outcomes. Explore the potential of new radiotracer targets and improved radiopharmaceutical production methods.
- Assess Clinical Implications: Analyze the potential impacts of these advancements on various medical fields, such as oncology, neurology, and cardiology. Discuss how these technologies could change the landscape of disease diagnosis, treatment planning, and patient management.
- Discuss Challenges and Opportunities: Highlight current challenges in the field, such as regulatory hurdles, production limitations, and cost implications. Provide insights into strategies for overcoming these challenges and leveraging emerging opportunities for better healthcare delivery.
Methodology: The article will be based on a comprehensive literature review, including recent publications, clinical trial data, and expert opinions. It will also incorporate interviews with leading researchers and practitioners in the field to provide current and future perspectives.
Significance: This article will offer valuable insights into the evolving field of PET/SPECT imaging and theranostics by addressing these objectives. It will help clinicians, researchers, and policymakers understand the potential of these technologies to transform medical practice and patient care, paving the way for more effective and personalized treatment options.
Conclusion: The future of PET/SPECT radiotracers and theranostics holds immense promise for advancing medical imaging and treatment. This Special Issue will provide a comprehensive overview of upcoming trends and their potential to revolutionize patient care, offering valuable knowledge to professionals and researchers.
Dr. Giuseppe Carlucci
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PET (Positron Emission Tomography)
- SPECT (Single-Photon Emission Computed Tomography)
- radiotracer chemistry
- radiotracers
- radiopharmaceutical
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
